Doctors rush to prescribe viral weight-loss drug retatrutide before approval

A wave of social-media hype around retatrutide is pulling doctors toward a drug that has not cleared FDA review for obesity or weight loss. One physician put the pressure plainly: "Why are we waiting?"

Retatrutide is Eli Lilly’s experimental triple-hormone agonist, targeting GIP, GLP-1 and glucagon receptors. It remains in clinical development, but the attention has surged because late-stage trial results showed striking weight-loss numbers, including an average loss of about 70.3 pounds over 80 weeks. In one reported subset, 45% of patients on the 12 mg dose lost up to 30% of their body weight. On social media, the drug has taken on a life of its own under the nickname “Triple G.”

That momentum has created a regulatory gray zone. Doctors who promote retatrutide openly are encouraging use before full approval and before the long-term safety profile is known, even as the drug continues in studies for obesity and related complications. The line between clinical judgment and marketing has become harder to see as patient demand rises around a drug that is still investigational.

Federal regulators have already signaled concern. The FDA has warned about unapproved GLP-1 drugs used for weight loss, including retatrutide sold online or compounded under labels such as “for research purposes” or “not for human use.” The agency says compounded drugs should generally be used only when patients’ medical needs cannot be met by an FDA-approved drug, and it has received complaints that some injectable GLP-1 products arrived warm or with inadequate refrigeration.

The pressure intensified after the FDA said on April 1, 2026, that the national tirzepatide shortage had been resolved. That shift altered the legal landscape for compounding pharmacies that had been supplying copycat products during shortages, while also underscoring how quickly the weight-loss-drug market has outpaced the rules built to govern it. Retatrutide has not been approved; for now, doctors pushing it into wider use are betting ahead of regulators and ahead of the data that still has to catch up.